BioInformant

Your Global Leader in Stem Cell Market Research

Home » news

Cord Blood Industry Consolidation Escalates as 2020 Approaches

By

The global cord blood industry experienced strong growth from the early 1990’s through the mid 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space.

Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation.

Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, and Latin America.

With CBR’s recent acquisition of Natera’s Evercord™ Cord Blood Business on September 13, 2019, the trend of cord blood industry consolidation continues. [Read more…]

Introducing the Dawn of MSCs with RoosterBio Founder, Jon Rowley

By

RoosterBioFounded by Dr. Jon Rowley, RoosterBio is a privately held stem cell tools and technology company focused on accelerating the development of a sustainable regenerative medicine industry. Its products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. I had the honor of interviewing Dr. Jon Rowley, who is now the CTO of RoosterBio.

In this interview, we explore RoosterBio’s recent product launches, collaborations, achievements and future trajectory.    [Read more…]

Oscine Therapeutics to Develop Stem Cell Therapies for CNS Disorders with Support from Sana Biotechnology

By

OscineOscine Therapeutics is a newcomer to the stem cell sector, a private biotech company exploring mechanisms for treating neurodegenerative disorders through the use of replacing lost or damaged glia cells. The company is based the renowned research of Steve Goldman, M.D., Ph.D., co-director of the University of Rochester Medical Center (URMC) Center for Translational Neuromedicine.

The focus of Dr. Goldman’s research has been to manipulate the chemical signaling of pluripotent stem cell types, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPS cells), to create healthy glia cells. [Read more…]

Minerva Biotechnologies, Interview with CEO Dr. Cynthia Bamdad

By

Minerva Biotechnologies is a regenerative medicine company specializing in stem cell therapeutics that is developing cancer immunotherapies to target 75% of solid tumors and to prevent cancer metastasis. I had the honor of interviewing Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies.

In this interview, we discuss Minerva’s technology platform, product portfolio, IP strategy, and strategic goals. We also explore the significance of the company’s AlphaSTEM™ Culture System that is a simple method for inducing the naïve state in human stem cells. Enjoy. [Read more…]

6 Trends Impacting the Cord Blood Industry

By

The cord blood industry came into existence in the early 1990’s with the formation of several leading cord blood banks in the U.S., followed by the formation of cord blood banks across the globe. It has now been almost 40 years since it was first proposed that stem and progenitor cells were present in human cord blood, so the question is, what will the next 40 years hold for the cord blood banking industry?

The last few years have been marked by substantial change, as explored below. [Read more…]

BioInformant's World-Class Clients